First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

WHO, 2021 Willett, 2022, The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism, medRxiv WHO, 2021 Santé publique France, 2022 Grabowski, 2021, Omicron strain spreads with the doubling time of 3.2–3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant, medRxiv Espenhain, 2021, Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, Eurosurveillance, 26, 10.2807/1560-7917.ES.2021.26.50.2101146 Barnard, 2021, Projected epidemiological consequences of the Omicron SARS-CoV-2 variant in England, December 2021 to April 2022, medRxiv Santé publique France, 2022 Maslo, 2021, Characteristics and outcomes of hospitalized patients in south africa during the covid-19 omicron wave compared with previous waves, JAMA, 30, e2124868 UKHSA, 2022 Vihta, 2022, Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom, medRxiv UKHSA, 2021 Ulloa, 2021, Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada, medRxiv Israel, 2022, COVID-19 severity prediction based on patient risk factors and number of vaccines received, medRxiv Andronico, 2021 Andrews, 2021, Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern, medRxiv Khoury, 2021, Analysis:a meta-analysis of early results to predict vaccine efficacy against omicron, medRxiv Collie, 2022, Effectiveness of BNT162b2 vaccine against omicron variant in South Africa, N Engl J Med, 386, 494, 10.1056/NEJMc2119270 Ahmed, 2021, SARS-CoV-2 T cell responses are expected to remain robust against Omicron, bioRxiv Keeton, 2021, SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron, medRxiv Santé publique France, 2022